Therapeutic potential of human amniotic membrane-derived mesenchymal stem cells in APP transgenic mice

Jiao, Hongliang; Shi, Ke; Zhang, Weijie; Yang, Liang; Yang, Lu; Guan, Fangxia; Yang, Bo

doi:10.3892/ol.2016.4857

Cited by 32 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, hAESCs improved spatial memory in double-transgenic mice by increasing acetylcholine levels and promoting the survival of cholinergic neurites in the hippocampus [24]. In addition, human placenta amniotic membrane-derived mesenchymal stem cells have been shown to reduce amyloid deposition in the brains of C57BL/6J-APP transgenic mice via oxidative stress regulation [26].…”

Section: Discussionmentioning

confidence: 94%

Therapeutic Effects of Human Amniotic Epithelial Stem Cells in a Transgenic Mouse Model of Alzheimer’s Disease

Kim

Suh

Chang

2020

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is characterized clinically by cognitive decline and pathologically by the development of amyloid plaques. AD is the most common cause of dementia among older people. However, there is currently no cure for AD. In this study, we aimed to elucidate the therapeutic effects of human amniotic epithelial stem cells (hAESCs) in a transgenic mouse model of AD. Tg2576 transgenic (Tg) mice underwent behavioral tests, namely the Morris water maze and Y-maze tests, to assess their cognitive function. In the Morris water maze test, hAESC-treated Tg mice exhibited significantly shorter escape latencies than vehicle-treated Tg mice. In the Y-maze test, hAESC-treated Tg mice exhibited significantly higher rate of spontaneous alteration than vehicle-treated Tg mice, while the total number of arm entries did not differ between the groups. Furthermore, Congo red staining revealed that hAESCs injection reduced the number of amyloid plaques present in the brains of Tg mice. Finally, beta-secretase (BACE) activity was significantly decreased in Tg mice at 60 min after hAESCs injection. In this study, we found that intracerebral injection of hAESCs alleviated cognitive impairment in a Tg2576 mouse model of AD. Our results indicate that hAESCs injection reduced amyloid plaques caused by reduced BACE activity. These results indicate that hAESCs may be a useful therapeutic agent for the treatment of AD-related memory impairment.

show abstract

Section: Discussionmentioning

confidence: 94%

Therapeutic Effects of Human Amniotic Epithelial Stem Cells in a Transgenic Mouse Model of Alzheimer’s Disease

Kim

Suh

Chang

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In addition, hAMSCs transplantation into transgenic mice increased the level of antioxidant enzymes and decreased the level of lipid peroxidation and oxidative stress (14).…”

Section: Supporting Evidence For Hypothesismentioning

confidence: 99%

“…Altogether, it seems that hAMSCs have potential therapeutic features that could be promising in MS therapy. There is some evidence for some hAMSCs properties including immunomodulation and inflammation suppression (11); angiogenesis promotion (12, 13); oxidative stress inhibition (14); neurogenesis induction and neuroprotection (15); matrix metalloproteinase regulation (16); and remyelination stimulation.…”

Section: Introductionmentioning

confidence: 99%

Potential Therapeutic Features of Human Amniotic Mesenchymal Stem Cells in Multiple Sclerosis: Immunomodulation, Inflammation Suppression, Angiogenesis Promotion, Oxidative Stress Inhibition, Neurogenesis Induction, MMPs Regulation, and Remyelination Stimulation

et al. 2019

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an inflammatory and degenerative disorder of the central nervous system with unknown etiology. It is accompanied by demyelination of the nerves during immunological processes in the presence of oxidative stress, hypoxia, cerebral hypo-perfusion, and dysregulation in matrix metalloproteinases (MMPs). Human amniotic mesenchymal stem cells (hAMSCs) as pluripotent stem cells possess some conspicuous features which could be of therapeutic value in MS therapy. hAMSCs could mimic the cascade of signals and secrete factors needed for promoting formation of stable neovasculature and angiogenesis. hAMSCs also have immunomodulatory and immunosuppressive effects on inflammatory processes and reduce the activity of inflammatory cells, migration of microglia and inhibit recruitment of certain immune cells to injury sites. hAMSCs attenuate the oxidative stress supported by the increased level of antioxidant enzymes and the decreased level of lipid peroxidation products. Furthermore, hAMSCs enhance neuroprotection and neurogenesis in brain injuries by inhibition of inflammation and promotion of neurogenesis. hAMSCs could significantly increase the expression of neurotrophic factors, which prevents neurons from initiating programmed cell death and improves survival, development, and function of neurons. In addition, they induce differentiation of neural progenitor cells to neurons. hAMSCs could also inhibit MMPs dysregulation and consequently promote the survival of endothelial cells, angiogenesis and the stabilization of vascular networks. Considering the mentioned evidences, we hypothesized here that hAMSCs and their conditioned medium could be of therapeutic value in MS therapy due to their unique properties, including immunomodulation and inflammation suppression; angiogenesis promotion; oxidative stress inhibition; neurogenesis induction and neuroprotection; matrix metalloproteinases regulation; and remyelination stimulation.

show abstract

“…In addition, human placental amniotic membrane-derived MSCs can improve the spatial learning and memory function of AD model mice. The number of amyloid plaques was also reduced, indicating that human placental amniotic membrane-derived MSC treatment might improve the pathology of AD and memory function through the regulation of oxidative stress [43]. Similarly, the transplantation of AD-MSCs can modulate microglial activation in AD mice, mitigate AD symptoms, and alleviate cognitive decline [44].…”

Section: Mscs In the Treatment Of Neurodegenerative Diseasesmentioning

confidence: 99%

Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Neurodegenerative Diseases

et al. 2020

View full text Add to dashboard Cite

Neurodegenerative disease is a kind of chronic, progressive nervous system disease characterized by neuron degeneration or apoptosis. Current treatments cannot prevent the development of the disease. Possible alternative treatments include cell therapy, especially with the use of mesenchymal stem cells (MSCs). MSCs are pluripotent stem cells with capacities for self-renewal and multidirectional differentiation. MSCs may serve as a reliable source of neural cells for potential cell replacement therapy or regenerative medicine treatment. Here, we summarized the therapeutic mechanisms of MSCs and how they can contribute to the development of treatments for neurodegenerative diseases.

show abstract

Therapeutic potential of human amniotic membrane-derived mesenchymal stem cells in APP transgenic mice

Cited by 32 publications

References 39 publications

Therapeutic Effects of Human Amniotic Epithelial Stem Cells in a Transgenic Mouse Model of Alzheimer’s Disease

Therapeutic Effects of Human Amniotic Epithelial Stem Cells in a Transgenic Mouse Model of Alzheimer’s Disease

Potential Therapeutic Features of Human Amniotic Mesenchymal Stem Cells in Multiple Sclerosis: Immunomodulation, Inflammation Suppression, Angiogenesis Promotion, Oxidative Stress Inhibition, Neurogenesis Induction, MMPs Regulation, and Remyelination Stimulation

Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Neurodegenerative Diseases

Contact Info

Product

Resources

About